Click on image to view larger version.
Figure 1. A) Simultaneous responses of cytosolic calcium and membrane potential in HUVEC following application of 100 ng/ml human recombinant VEGF165. The time of addition of VEGF165 is indicated by the vertical line. For comparison, control responses to VEGF165 obtained from Figure 1
A are represented by a dotted line without error bars in panels B–D. B) Effect of VEGFR-2 inhibition on calcium transients and membrane depolarization after application of 100 ng/ml VEGF165. C) Effect of pretreatment of HUVEC with LOE-908, the nonselective cation channel blocker (NSCC1 and NSCC2) on calcium and membrane potential responses to VEGF165. D) Effect of pretreatment of HUVEC with SKF96365, the store-operated and nonselective cation channel blocker (SOC and NSCC2), on calcium and membrane potential responses to VEGF165.
